Pharma makes the highest-stakes, longest-cycle decisions of any industry , and applies extraordinary rigour to the clinical half of that process. The challenge that the sector is actively working through is how to extend that same discipline to the strategic assumptions that sit above the science: which therapy areas to prioritise, whether payer access will follow regulatory approval, and whether the commercial thesis that justified a decade of investment will still hold when a drug reaches the market.
There is a structural feature of pharmaceutical decision-making that makes it unlike any other industry in this series: the length of the commitment horizon. A therapy area prioritisation decision made today will produce a clinical outcome in seven to twelve years. The commercial assumptions embedded in that decision , what the competitive landscape will look like, whether payer willingness to reimburse will hold, whether the regulatory pathway will remain navigable , are assumptions about a world a decade away.
What the industry has built to manage this is genuinely impressive on the clinical side. Trial design standards, ethics review, data monitoring committees, real-world evidence platforms, regulatory intelligence tools. The evidentiary discipline applied to a Phase III endpoint is world-class. The challenge , and it is a structural one, not a capability one , is that the strategic decisions above the science operate on a different infrastructure. Therapy area prioritisation, launch sequencing, pricing architecture, payer access strategy: these are governed primarily by financial models and strategy decks, reviewed annually rather than continuously, and rarely documented in a form that survives the leadership transitions they will inevitably outlast.
The research on what this costs is substantial. The industry invested over $300 billion in R&D in 2025,[2] with the average cost per approved drug reaching $2.23 billion in 2024.[3] Against that baseline, $7.7 billion was spent on terminated candidates in 2024 alone,[1] and over 60% of drug launches still fail to meet their pre-launch commercial forecasts , with market access and reimbursement complexity identified as the leading driver, ahead of clinical differentiation or promotional execution.[4] Understanding where in the decision process these outcomes are shaped , and what can be done earlier to improve them , is what this article is about.
What is the Decision Lifecycle?
The Decision Lifecycle is the end-to-end process through which a strategic decision moves from signal to institutional learning. Defined and applied to industry strategy by Ranjan Kumar at DecisionX, it comprises three stages: Pre-Decision , sensing signals, assembling context, and reasoning before commitment; Decision , making the call and capturing the reasoning as a persistent object with explicit, trackable assumptions; and Post-Decision , monitoring those assumptions, running root cause analysis when outcomes diverge, and converting that learning into the next cycle. In pharma, clinical outcome tracking at the Post-Decision stage is as rigorous as any industry in the world. The opportunity is building an equivalent layer of rigour for the strategic assumptions , competitive, regulatory, and payer , that determine whether a clinical success translates into a commercial one.
Below is how pharma scores across all three stages, based on research from Deloitte, McKinsey, mama health, Advaiya, DrugPatentWatch, PharmExec, and Everest Group. The scores reflect structural patterns across the industry. Click any stage to explore where the complexity lives and the evidence behind it.
Before examining each stage, it is worth understanding the structural feature that makes pharma's Decision Lifecycle uniquely challenging: the length of the arc. A pipeline decision made today produces a clinical outcome in seven to twelve years. The commercial assumptions embedded in that decision , what the competitive landscape will look like, what payer willingness to reimburse will be, whether the regulatory pathway will remain navigable , are assumptions about a world a decade away.
No other industry in this series makes this kind of capital commitment against this kind of time horizon against a background environment that is actively and sometimes rapidly shifting. The IRA has already moved revenue cliffs forward by years,[5] drugs with combined annual revenues of approximately $350 billion face patent expiration between 2025 and 2029,[6] and 87% of surveyed executives say the IRA has already led them to alter launch plans for specific diseases or therapeutic areas.[7] Each of those plan changes represents a therapy area prioritisation decision whose commercial assumptions have shifted within the development window , which is exactly the kind of signal that a formal assumption-tracking process at Phase gates is designed to surface early enough to act on.
Pharma's Pre-Decision environment is genuinely data-rich. Clinical trial data systems. Real-World Evidence platforms. IQVIA and Symphony Health market data. Regulatory intelligence tools. Payer and reimbursement databases. For many industries, this would be an aspirational standard. In pharma, it is the baseline. The inputs for a well-reasoned pipeline decision exist in abundance.
The challenge , and it is a structural one common to most large R&D organisations, not a pharma-specific failure , is that these inputs are assembled by separate functions for separate purposes, not synthesised into a unified reasoning context around a specific pipeline commitment. Three specific gaps are worth understanding on their own terms:
For many pharma organisations, planning for commercialisation only truly begins when a drug has been submitted for approval , far too late in the process.[8] The payer evidence gap that will determine reimbursement is identifiable years before approval. But the teams that understand it are not routinely in the room when pipeline decisions are made.
Most pharma R&D functions still manage portfolios across multiple spreadsheet files, maintained by different people, updated on different schedules.[1] Scenario analysis , what does our portfolio look like if this Phase III fails, if a competitor launches first, if the IRA negotiation clock starts here , happens once a year. Not when a decision needs to be made.
Decision criteria in pharma harden quickly. A therapy area that looks differentiated at pipeline entry may face two new competitors by Phase III. The pre-decision intelligence exists to track competitive development publicly on ClinicalTrials.gov , but systematically integrating it into pipeline reasoning before commitment is rarely done with rigour.
The consequence of these three structural gaps is that pharma's most consequential pipeline decisions , therapy area entry, Phase gate go/no-go, launch sequence , are made with strong clinical reasoning assembled in one track and commercial, competitive, and payer reasoning assembled in a separate, later one. As the industry itself is working to address, bringing market access and competitive intelligence into early pipeline review is not a minor procedural change , it substantively changes which assumptions get stress-tested before capital scales. As PharmExec's analysis of early-stage drug development noted: executive decision-making should find the optimal balance between effort and value , and the evidence increasingly supports that earlier cross-functional synthesis produces better-calibrated commitments.[9]
These are the questions that define the hardest calls in pharmaceutical strategy. Each one requires simultaneous reasoning across clinical, commercial, regulatory, and competitive domains , and the answer to each changes significantly depending on how the others resolve:
What makes these questions particularly hard in pharma is that they are genuinely cross-functional , and the functions that need to reason together are structurally separated in most organisations. R&D owns the pipeline. Commercial owns the forecast. Market access owns payer strategy. Regulatory owns the approval pathway. The question "where is the payer evidence gap we need to close during the trial?" requires all four simultaneously. Most pipeline review processes surface answers from each function in sequence , not together.
Pharma's Decision stage scores 36/100 , and the score reflects a specific and understandable structural gap rather than a governance failure. The clinical decision infrastructure is genuinely rigorous: trial design standards, ethics review, data monitoring committees, regulatory submission requirements. These are hard-won, carefully designed, and rightly central to how the industry operates.
What sits alongside that clinical rigour, but is less developed, is the infrastructure for capturing the strategic reasoning that governs the investment decisions above the clinical process. As World Pharma Today noted in 2025, drawing on analysis of pharma R&D portfolio management across the industry: decision rationales go undocumented.[1] A therapy area prioritisation decision , a five-year, multi-billion dollar R&D commitment , is made through a rigorous pipeline review process. The financial model is built with care. The board approves with appropriate deliberation. What is not routinely captured is the reasoning that justified the choice: the three commercial assumptions the investment rests on, in a form that can be reviewed at each Phase gate and interrogated when outcomes diverge.
The challenge this creates is compounded by the length of the decision arc. The average pharma CEO tenure is approximately four years.[10] A pipeline decision made today will not reach commercial realisation under the leadership that approved it. This is not a critique of leadership decisions , it is a structural feature of an industry with uniquely long development timelines. The practical implication is that the reasoning behind a live pipeline commitment needs to be documented in a form that is independent of the people who produced it. Currently, it largely is not.
The most consequential and most common strategic commitment in pharma: choosing which therapy area to prioritise for the next five-year R&D investment cycle. The scientific rationale is documented extensively. The three assumptions that determine whether the commercial rationale holds are almost never tracked:
The competitive landscape in the chosen therapy area will remain navigable through the development window , no competitor will define the standard of care and set the reimbursement benchmark before our asset reaches Phase III.
The regulatory pathway will remain consistent with the approval assumptions modelled at the time of the decision , the endpoints, the trial design requirements, and the evidentiary standard will not shift materially mid-development.
Payer willingness to reimburse will be comparable to analogous approvals in the same class , the health technology assessment landscape will not have tightened to the point where clinical approval no longer predicts market access.
All three are reasonable assumptions to make at the point of commitment. All three are also assumptions about a world seven to ten years away, in a regulatory, competitive, and payer environment that is actively evolving. The IRA provides a clear and recent illustration of how payer willingness assumptions can shift materially within a development window: 78% of executives report expecting to cancel early-stage small-molecule pipeline projects in response to IRA economics.[11] These projects were approved under a pricing and revenue assumption that the broader environment has since changed. A formal assumption-tracking process at each Phase gate , reviewing whether the IRA economics still support the original investment thesis , would surface that signal earlier, when more options for adaptation remain available.
This is where pharma's profile diverges most sharply from every other industry in this series , and the score of 14/100 needs to be understood precisely, because the reason for it is both specific and constructive.
Pharma is not weak at post-decision tracking. It is the strongest post-decision tracking industry in this series on the clinical side. Adverse events, endpoint achievement, protocol deviations, survival curves, real-world evidence , all documented, all interrogated, all available for meta-analysis. The clinical record is extraordinary, and it has produced genuine advances in how the industry designs, monitors, and learns from trials. That infrastructure took decades to build and represents genuine institutional achievement.
The opportunity , and this is where the 14/100 score is grounded , is building an equivalent layer alongside it for the strategic assumptions that determine whether a clinical success translates into a commercial one. The competitive assumptions, the regulatory pathway assumptions, and the payer evidence assumptions that were embedded in the pipeline and launch decisions are not currently reviewed at Phase gates or quarterly launch performance reviews. They surface when the outcome diverges significantly from forecast , at which point, as Deloitte's launch performance analysis shows, the primary diagnosis lands on market access or sales execution rather than tracing to the original pipeline assumption that shaped the launch strategy.[12]
ZS Associates' retrospective on 340 brand launches between 2008 and 2025 found that clinical differentiation alone produces a 49% overperformance rate , but clinical differentiation combined with strong manufacturer commitment produces 67%, an 18-point gap that has almost nothing to do with the molecule.[13] That commercial commitment is built 24 to 36 months before launch , through assumption tracking, payer evidence investment, and access strategy , not through execution at launch. Tirzepatide's trajectory, the steepest sustained commercial ramp in pharmaceutical history, was built on exactly this principle. Aduhelm's $4.6 million first-year sales, against a $56,000 annual price with no clear CMS coverage, illustrates what happens when the payer access assumption goes untracked until launch.[13] Both outcomes were substantially shaped before the launch date by decisions made , or not made , years earlier.
Specialty drugs routinely face nine to fifteen months of limited formulary coverage before achieving broad payer access.[14] A launch model that does not build this into its Year 1 assumptions will generate a guidance miss that will be attributed to market conditions. The miss is real , but it is predictable, and the tools to predict it exist in the payer intelligence and market access functions that are already part of every major pharma organisation. What is needed is a mechanism to bring those insights into the assumption record of the pipeline decision, and to review them at each Phase gate rather than only at launch.
Looking across all three stages, the picture that emerges is one of an industry that has invested heavily and effectively in the most visible and most regulated parts of the decision process , the clinical trial, the regulatory submission, the approval. The next frontier is building equivalent rigour into the strategic layer that sits above the clinical process.
The good news is that the infrastructure for this already largely exists. The data platforms are there. The Phase gate process is there. The market access, regulatory intelligence, and competitive intelligence functions are there. What completing the Decision Lifecycle adds is the connective tissue: a mechanism to assemble those inputs as a cross-functional reasoning context before commitment; a Reasoning Object that names the strategic assumptions at the point of approval; and a formal assumption review at each Phase gate alongside the clinical data package.
None of this is a large addition to what already exists. A therapy area prioritisation decision that names three commercial assumptions at approval , with a monitoring owner and a review cadence at each Phase gate , is not a materially different governance process. It is the same process with one additional layer that makes it compounding rather than episodic. Each launch cycle learns from the assumption failures of the last. Each pipeline entry is made with better-calibrated expectations about the commercial environment it will enter.
The evidentiary discipline that governs a Phase III endpoint can be applied , in lighter, more practical form , to the competitive, regulatory, and payer assumptions that govern a therapy area commitment. Not to slow the pipeline down, but to make each decision in it smarter than the last. That is what a complete Decision Lifecycle makes possible , and what the industry's $300 billion annual R&D investment has the most to gain from building.
About this series
Decision Made ≠ Decision Done applies the Decision Lifecycle framework , developed by Ranjan Kumar at DecisionX , to the strategic decisions that define each industry. Each article maps where the genuine complexity sits across Pre-Decision, Decision, and Post-Decision stages, and what building better looks like in each context.
Article 1 , D2C (Global) · Article 2 , CPG · Article 3 , Manufacturing · Article 4 , India D2C · Article 5 , Pharma (this article) · .
Ranjan Kumar is the Founder and CEO of DecisionX AI, the world’s first self-learning, context-aware Decision Intelligence platform that enables enterprises to make smarter, faster business decisions through agentic AI. A serial entrepreneur and three-time founder with over 17 years of experience, Ranjan previously built Entropik, the world’s first Emotion AI platform with 17 global patent claims. An IIT Kharagpur alumnus, he is widely recognized as a thought leader in enterprise AI, Ontology Engineering, decision reasoning, and AI-driven business transformation.
